{"id":43500,"date":"2023-06-29T13:40:56","date_gmt":"2023-06-29T05:40:56","guid":{"rendered":"https:\/\/biopioneer.com.tw\/?p=43500"},"modified":"2023-07-04T16:03:55","modified_gmt":"2023-07-04T08:03:55","slug":"secukinumab-ain457-%e6%8a%97-il-17-%e8%97%a5%e7%89%a9-abmole%e8%b2%a8%e8%99%9fm1622","status":"publish","type":"post","link":"http:\/\/biopioneer.com.tw\/?p=43500","title":{"rendered":"Secukinumab (AIN457) \u6297 IL-17 \u85e5\u7269 | abmole\u8ca8\u865fM1622"},"content":{"rendered":"

Secukinumab (AIN457) \u6297 IL-17 \u85e5\u7269| abmole\u8ca8\u865fM1622<\/span><\/a>
\nCat. No. M1622<\/p>\n

<\/p>\n

Secukinumab (AIN457) \u662f\u4e00\u7a2e\u91dd\u5c0d\u767d\u7d30\u80de\u4ecb\u7d20 (IL-17A) \u7684\u9ad8\u89aa\u548c\u529b\u55ae\u514b\u9686\u6297\u9ad4\u3002 Secukinumab (AIN457) \u662f\u6591\u584a\u72c0\u9280\u5c51\u75c5\u3001\u5f37\u76f4\u6027\u810a\u67f1\u708e\u548c\u9280\u5c51\u75c5\u95dc\u7bc0\u708e\u7814\u7a76\u4e2d\u7684\u4e00\u6d41\u6297 IL-17 \u85e5\u7269\u3002<\/p>\n

Biological Activity<\/span><\/strong><\/span><\/h5>\n

Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is a first-in-class anti-IL-17 agent in the study of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.<\/p>\n

Chemical Information<\/span><\/strong><\/span><\/h5>\n\n\n\n\n\n\n
Molecular Weight<\/td>\n147941.89<\/td>\n<\/tr>\n
Formula<\/td>\nC6584H10134N1754O2042S44<\/td>\n<\/tr>\n
CAS Number<\/td>\n875356-43-7<\/a><\/td>\n<\/tr>\n
Storage<\/td>\n-80\u00b0C for long term<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Conversion of different model animals based on BSA (PMID: 27057123)<\/span><\/strong><\/h6>\n\n\n\n\n\n\n
Species<\/td>\nMouse<\/td>\nRat<\/td>\nRabbit<\/td>\nGuinea pig<\/td>\nHamster<\/td>\nDog<\/td>\n<\/tr>\n
Weight (kg)<\/td>\n0.02<\/td>\n0.15<\/td>\n1.8<\/td>\n0.4<\/td>\n0.08<\/td>\n10<\/td>\n<\/tr>\n
Body Surface Area (m2<\/sup>)<\/td>\n0.007<\/td>\n0.025<\/td>\n0.15<\/td>\n0.05<\/td>\n0.02<\/td>\n0.5<\/td>\n<\/tr>\n
Km<\/sub>\u00a0factor<\/td>\n3<\/td>\n6<\/td>\n12<\/td>\n8<\/td>\n5<\/td>\n20<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
Animal A (mg\/kg) = Animal B (mg\/kg) multiplied by<\/td>\nAnimal B Km<\/sub><\/td>\n<\/tr>\n
Animal A Km<\/sub><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

For example, to modify the dose of Compound A used for a mouse (20 mg\/kg) to a dose based on the BSA for a rat, multiply 20 mg\/kg by the Km<\/sub>\u00a0factor for a mouse and then divide by the Km<\/sub>\u00a0factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg\/kg.<\/p>\n

<\/p>\n

\"DM\u76ee\u9304_\u5de5\u4f5c\u5340\u57df<\/a><\/p>\n

References<\/span><\/strong><\/span><\/h5>\n

[1] Kristian Reich,\u00a0et al. N Engl J Med. Bimekizumab versus Secukinumab in Plaque Psoriasis<\/p>\n

[2] Hannah A Blair. Drugs. Secukinumab: A Review in Psoriatic Arthritis<\/p>\n

[3] Hannah A Blair. Drugs. Secukinumab: A Review in Ankylosing Spondylitis<\/p>\n

[4] Lubrano E,\u00a0et al. Ther Clin Risk Manag. Secukinumab for ankylosing spondylitis and psoriatic arthritis.<\/p>\n

[5] Dominique Baeten,\u00a0et al. N Engl J Med. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis<\/p>\n

[6] Richard G Langley,\u00a0et al. N Engl J Med. Secukinumab in plaque psoriasis–results of two phase 3 trials<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Secukinumab (AIN457) \u6297 IL-17 \u85e5\u7269| abmole\u8ca8\u865fM1622 Cat. No. […]<\/p>\n","protected":false},"author":3,"featured_media":43502,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5888],"tags":[5895],"_links":{"self":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/43500"}],"collection":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43500"}],"version-history":[{"count":3,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/43500\/revisions"}],"predecessor-version":[{"id":43506,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/43500\/revisions\/43506"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/43502"}],"wp:attachment":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43500"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}